Abstract:The use of immunosuppressive agents, especially glucocorticoids, are associated with increased risks of bone loss in kidney transplant patients. Denosumab, a potent antiresorptive agent, has been shown to increase bone mineral density (BMD) in patients with CKD. However, its effects on bone metabolism and BMD in kidney transplant patients remain unclear.A literature search was conducted using MEDLINE, EMBASE, and Cochrane Database from inception through April 2018 to identify studies evaluating denosumab's effect on changes in bone metabolism and BMD from baseline to post-treatment course in kidney transplant patients. Study results were pooled and analyzed utilizing random-effects model. The protocol for this systematic review is registered with PROSPERO (International Prospective Register of Systematic Reviews; no. CRD42018095055).Five studies (a clinical trial and four cohort studies) with a total of 162 kidney transplant patients were identified. The majority of patients had a baseline eGFR ≥ 30 mL/min/1.73 m2. After treatment (≥ 6 to 12 months), there were significant increases in BMD with standardized mean differences (SMDs) of 3.26 (95% CI 0.88–5.64) and 1.83 (95% CI 0.43 to 3.22) for lumbar spine and femoral neck, respectively. There were also significant increases in T scores with SMDs of 0.92 (95% CI 0.58 to 1.25) and 1.14 (95% CI 0.17 to 2.10) for lumbar spine and femoral neck, respectively. After treatment, there were no significant changes in serum calcium (Ca) or parathyroid hormone (PTH) from baseline to post-treatment course (≥ 6 months) with mean differences (MDs) of 0.52 (95% CI, − 0.13 to 1.16) mmol/L and − 13.24 (95% CI, − 43.85 to 17.37) ng/L, respectively. The clinical trial data demonstrated more asymptomatic hypocalcemia in the denosumab (12 episodes in 39 patients) than in the control (1 episode in 42 patients) group. From the cohort studies, the pooled incidence of hypocalcemia following denosumab treatment was 1.7% (95% CI 0.4 to 6.6%). All reported hypocalcemic episodes were mild and asymptomatic, but the majority of patients required Ca and vitamin D supplements.Among kidney transplant patients with good allograft function, denosumab effectively increases BMD and T scores in the lumbar spine and femur neck. From baseline to post-treatment, there are no differences in serum Ca and PTH. However, mild hypocalcemia can occur following denosumab treatment, requiring monitoring and titration of Ca and vitamin D supplements.

Anti-RANKL Antibody For Active Charcot Foot Neuro-Osteoarthropathy in Patients with Diabetes and Chronic Kidney Disease

Effect of denosumab on inflammation and bone health in active Charcot foot: A phase II randomised controlled trial

Genetic Signature for the Causation of Charcot Neuro-osteoarthropathy of Foot in Diabetes: A Systematic Review

Early Treatment of Acute Stage 0/1 Diabetic Charcot Foot Can Avoid Major Amputations at One Year

A prospective randomized controlled trial of bone metabolism in patients with charcot foot

Denosumab, for osteoporosis, reduces the incidence of type 2 diabetes, risk of foot ulceration and all‐cause mortality in adults, compared with bisphosphonates: An analysis of real‐world, cohort data, with a systematic review and meta‐analysis

Diabetic Charcot neuroarthropathy: A threat to both limb and life

Biomarkers for Early Detection of Charcot Arthropathy: A Prospective Study on Type 2 Diabetes Patients with Severe Neuropathy

Association of denosumab with serum cytokines, chemokines, and bone-related factors in patients with rheumatoid arthritis: A post hoc analysis of a multicentre, open-label, randomised, parallel-group study

Denosumab for osteoporosis in patients suffering from chronic kidney disease; a review on current data

Effect of denosumab, an anti-osteoporosis drug, on vascular calcification: A meta-analysis

Anti-RANKL treatment improves screw fixation in cancellous bone in rats

Association of Anatomical Location of Neuroarthropathic (Charcot’s) Destruction with Age-and Sex-Matched Bone Mineral Density Reduction

RANKL as a target for the treatment of osteoporosis

Type 2 diabetes incidence in patients initiating denosumab or alendronate treatment: a primary care cohort study

Therapeutic Benefits of Neoadjuvant and Post-Operative Denosumab on Sacral Giant Cell Tumor: a Retrospective Cohort Study of 30 Cases.

Charcot neuroarthropathy in persons with diabetes: It's time for a paradigm shift in our thinking

Efficacy and Safety of Denosumab from A Phase Iii, Randomized, Active-Controlled Study Compared with Zoledronic Acid in Patients of Asian Ancestry with Bone Metastases from Solid Tumors.

Exploring Denosumab's potential in aneurysmal bone cyst treatment: A scoping review

Effects of denosumab on bone metabolism and bone mineral density in kidney transplant patients: a systematic review and meta-analysis

Immune modulation with RANKL blockade through denosumab treatment in patients with cancer